Welcome to our dedicated page for Compass Therapeutics news (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.
Compass Therapeutics, Inc. (Nasdaq: CMPX) is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. News about CMPX often centers on its antibody pipeline, clinical trial progress, financing activities, and corporate developments, reflecting its focus on angiogenesis, immune modulation, and tumor growth.
Investors and observers following Compass Therapeutics news can expect regular updates on key product candidates such as tovecimig, CTX-8371, CTX-10726, and CTX-471. The company issues press releases on milestones in the COMPANION-002 Phase 2/3 study of tovecimig in advanced biliary tract cancer, monotherapy data in metastatic colorectal cancer, and cohort expansions or new responses in the Phase 1 study of CTX-8371 in indications like non-small cell lung cancer, triple negative breast cancer, and Hodgkin Lymphoma. Preclinical data releases for CTX-10726, including presentations at scientific meetings, also feature prominently.
Compass Therapeutics news coverage additionally includes quarterly financial results, cash and marketable securities updates, and descriptions of anticipated cash runway, as disclosed in earnings press releases and related Form 8-K filings. The company also announces public offerings of common stock and pre-funded warrants, with details on intended use of proceeds for research, clinical development, and preparations for potential commercialization.
Another recurring theme in CMPX news is participation in healthcare and biopharma investor conferences, where Compass presents its pipeline and corporate strategy. Press releases list appearances at events hosted by firms such as J.P. Morgan, Piper Sandler, Evercore, Guggenheim, Stifel, Cantor, and others. Leadership appointments, including additions to the senior management team, are also communicated through Globe Newswire releases.
This news page aggregates these company-issued updates and related coverage, offering a centralized view of clinical, scientific, financial, and corporate developments for Compass Therapeutics and its CMPX stock.
Compass Therapeutics, Inc. (Nasdaq: CMPX) will present at the 2022 Wedbush PacGrow Healthcare Conference, scheduled virtually for August 9-10, 2022. The presentation is set for August 9 at 4:05 pm ET. Interested parties can access the webcast here, and it will be available for replay for 90 days on Compass’s Events page.
Compass Therapeutics focuses on developing antibody-based therapeutics aimed at treating cancer by targeting critical biological pathways.
Compass Therapeutics (CMPX) reported Q2 2022 results with a net loss of $8.5M ($0.08/share), down from $55.8M ($1.07/share) in Q2 2021. Cash and marketable securities totaled $132M, extending their runway into H2 2024. The company is set to initiate a Phase 2/3 trial for CTX-009 in biliary tract cancer (BTC) and a Phase 2 trial for advanced colorectal cancer (CRC) by Q4 2022. Additionally, CTX-471 continues to show efficacy in mesothelioma patients, with four reported partial responses. R&D expenses rose to $5.9M from $2.9M, while G&A expenses increased to $3.1M from $2.2M, reflecting ongoing operational growth.
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company, will present at the 2022 Jefferies Global Healthcare Conference on June 9, 2022, at 8:00 am ET in New York City. The presentation will focus on the company's proprietary antibody-based cancer therapeutics. It will be available for live streaming and archived for 90 days on their website. Compass Therapeutics aims to advance innovative therapies targeting critical biological pathways in oncology.
Compass Therapeutics, a clinical-stage biopharmaceutical company focused on antibody-based cancer treatments, announced that CEO Thomas J. Schuetz will present at the 2022 H.C. Wainwright Global Investment Conference from May 23-26, 2022. The webinar will be available on-demand starting May 24, 2022, at 7:00 a.m. ET, and can be accessed through their website. Compass Therapeutics is dedicated to developing therapies targeting angiogenesis and immune response mechanisms to combat tumors, with a pipeline aimed at advancing multiple product candidates.
Compass Therapeutics, Inc. (CMPX) announced the FDA's approval of the investigational new drug application for CTX-009, allowing an expansion to a global Phase 2 study in biliary tract cancer. Interim data indicated a 42% overall response rate (ORR) and a 92% clinical benefit rate (CBR) among the first 24 patients. The CTX-471 Phase 1b study reported 3 partial responses. As of March 31, 2022, the company had $136.4 million in cash, anticipated to fund operations into late 2024, with a reduced net loss of $7.2 million for Q1 2022, compared to $7.3 million in Q1 2021.
Compass Therapeutics, a clinical-stage biopharmaceutical company focused on antibody-based cancer treatments, announced that CEO Thomas J. Schuetz will present at the Bank of America Securities 2022 Healthcare Conference. The event is set for May 12, 2022, at 11:20 AM PT in Las Vegas. The presentation will be available live and replayed 24 hours post-event on the company's website. Compass is dedicated to developing therapies targeting critical biological pathways essential for effective anti-tumor responses.
Compass Therapeutics (Nasdaq: CMPX) announced interim results from its Phase 2 study of CTX-009, revealing a 42% overall response rate (ORR) based on 10 partial responses among 24 patients with biliary tract cancers. The clinical benefit rate reached 92%, with most patients exhibiting stable disease. The drug was well tolerated, aligning with Phase 1 findings. Compass plans to commence the second stage of the study in the U.S. in Q3 2022. The data suggest CTX-009 may offer a new treatment avenue for patients with limited options.
Compass Therapeutics, Inc. (Nasdaq: CMPX) will host a webinar on May 4, 2022, at 8:00 a.m. ET to discuss clinical data from its ongoing Phase 2 trial of CTX-009. A Key Opinion Leader will join the management for this review. The company focuses on developing proprietary antibody-based therapeutics targeting cancer through a unique approach addressing angiogenesis and immune response. The upcoming session aims to provide insights into trial results, with a replay available for six months on the company's website.
Compass Therapeutics, Inc. (Nasdaq: CMPX) announced the appointment of two new directors, Ellen Chiniara and Mary Ann Gray, to its board. Chiniara, former Chief Legal Officer of Alexion Pharmaceuticals, and Gray, President of Gray Strategic Advisors, bring extensive experience in the life sciences and biopharmaceutical sectors. This strategic move aims to enhance Compass's leadership at a critical time for the company. The board believes their skills will support Compass in advancing its clinical pipeline and driving shareholder value.
Compass Therapeutics (CMPX), a clinical-stage oncology company, recently presented promising preclinical data for its bispecific checkpoint inhibitor, CTX-8371, at the AACR Annual Meeting. This innovative therapy targets both PD-1 and PD-L1, showcasing a unique mechanism of action that leads to PD-1 loss on T cells. Key findings indicate significant tumor volume reduction and complete tumor eradication in mouse models. Clinical development of CTX-8371 is projected to start in early 2023, marking a significant step forward in cancer therapeutics.